Vonoprazan is noninferior to proton pump inhibitors in bismuth‐containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis

VPZ-based therapy resulted in a satisfactory eradication rate and was well tolerated for H. pylori eradication, which are comparable to PPIs in C-BQT as a first-line treatment for H. pylori infection.